mFOLFOX系统性化疗联合靶向免疫方案治疗不可切除肝细胞癌的真实世界数据初步分析

doi:10.3969/j.issn.1009-976X.2023.04.002

岭南现代临床外科 ›› 2023, Vol. 23 ›› Issue (04): 294-301.DOI: 10.3969/j.issn.1009-976X.2023.04.002

mFOLFOX系统性化疗联合靶向免疫方案治疗不可切除肝细胞癌的真实世界数据初步分析

罗旋, 龙吟, 黄子棋, 何晓东, 黄珏, 廖建国, 张磊^*

中山大学孙逸仙纪念医院肝胆外科,广州 510120

通讯作者: *张磊,zhangl9@mail.sysu.edu.cn
基金资助:
广州市基础研究计划市校联合资助项目（202201020301）

Real-world analysis of mFOLFOX systemic chemotherapy combined with immunotherapy and targeted therapy for unresectable hepatocellular carcinoma

LUO Xuan, LONG Yin, HUANG Zi-qi, HE Xiao-dong, HUANG Jue, LIAO Jian-guo, ZHANG Lei

Department of Hepatobiliary, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China

Received:2023-06-12 Online:2023-08-20 Published:2023-11-30
Contact: ZHANG Lei,zhangl9@mail.sysu.edu.cn

摘要/Abstract

摘要： 目的初步评估mFOLFOX系统性化疗联合靶向免疫方案应用于不可切除肝细胞癌（uHCC）的真实世界疗效和安全性。方法回顾性收集并分析2022年7月至2023年7月期间中山大学孙逸仙纪念医院肝胆外科收治的51例应用mFOLFOX联合免疫靶向方案治疗uHCC患者的真实世界数据。结果初步统计mRECIST标准下客观缓解率（ORR）为47.1%,疾病控制率（DCR）为96.1%;其中21例（41.2%）成功转化手术,术后5例达到pCR（23.8%）。Logistic回归分析显示肿瘤数量是达到转化的独立影响因素（OR=11.6,95%CI：1.28~105.41,P=0.029）,而治疗时机可能是临床上影响缓解的独立因素,但未达到统计学差异（P=0.054）。平均随访时间为6.76个月,中位OS及PFS均未达到。治疗相关不良事件（TRAE）总体发生率为92.1%。其中3~4级TRAE发生率为33.3%。结论 mFOLFOX系统性化疗联合靶向免疫方案可安全有效地应用于不可切除肝癌的治疗,并有可观的转化手术率。

关键词: FOLFOX, 系统性化疗, 不可切除肝癌, 转化手术

Abstract: Objective To evaluate the real-world efficacy and safety of mFOLFOX systemic chemotherapy combined with immunotherapy and targeted therapy for unresectable hepatocellular carcinoma （uHCC）. Method The real-world data of 51 patients with uHCC treated by mFOLFOX combined with immunotherapy and targeted therapy in the Hepatobiliary Department of Sun Yat-sen Memorial Hospital from July 2022 to July 2023 were retrospective collected and analyzed. Results According to the preliminary statistics, the objective response rate （ORR） and disease control rate （DCR） under the mRECIST standard were 47.1% and 96.1% respectively; Among them, 21 cases （41.2%） successfully underwent conversion surgery, and 5 cases achieved pCR （23.8%） after surgery. Logistic regression analysis showed that the number of tumors was an independent influencing factor for achieving conversion （OR=11.6, 95% CI：1.28~105.41, P=0.029）, while treatment timing may be an independent clinical factor affecting remission, but there was no statistically significant difference （P=0.054）. The average follow-up time was 6.76 months, and the median OS and PFS were not achieved. The overall incidence of treatment related adverse events （TRAE） was 92.1% and the incidence of level 3~4 TRAE is 33.3%. Conclusion mFOLFOX systemic chemotherapy combined with immunotherapy and targeted therapy can be safely and effectively applied to the treatment of unresectable hepatocellular carcinoma, with a considerable conversion surgery rate.

Key words: FOLFOX, systemic chemotherapy, unresectable hepatocellular carcinoma, conversion surgery

中图分类号:

罗旋, 龙吟, 黄子棋, 何晓东, 黄珏, 廖建国, 张磊. mFOLFOX系统性化疗联合靶向免疫方案治疗不可切除肝细胞癌的真实世界数据初步分析[J]. 岭南现代临床外科, 2023, 23(04): 294-301.

LUO Xuan, LONG Yin, HUANG Zi-qi, HE Xiao-dong, HUANG Jue, LIAO Jian-guo, ZHANG Lei. Real-world analysis of mFOLFOX systemic chemotherapy combined with immunotherapy and targeted therapy for unresectable hepatocellular carcinoma[J]. Lingnan Modern Clinics In Surgery, 2023, 23(04): 294-301.

参考文献

[1] 中华医学会糖尿病学分会,中华医学会感染病学分会,中华医学会组织修复与再生分会. 中国糖尿病足防治指南(2019版)[J].中华糖尿病杂志,2019,11(2):92-108.
[2] International Diabetes Federation. IDF Diabetes Atlas, 8th. Brussels:2017[EB/OL]. [2019-01-02]. http://www.diabetesatlas.org.
[3] Bakker K, Apelqvist J, Lipsky BA,et al.The 2015 IWGDF guidance documents on prevention and management of foot problems in diabetes: development of an evidence-based global consensus[J]. Diabetes Metab Res Rev,2016,32(Suppl 1):S2-6.
[4] Zakaria Z, Afifi M, Sharifud IN MA.Clinical Factors affecting Minor Amputation in Diabetic Foot Disease at Tengku Ampuan Afzan Hospital, Kuantan[J]. Malays J Med Sci, 2015,22(2):41-47.
[5] Yusof NM, Rahman JA, Zulkifly AH, et al.Predictors of major lower limb amputation among type II diabetic patients admitted for diabetic foot problems[J]. Singapore Med J,2015,56(11):626-631.
[6] 朱潇潇, 刘一苇, 霍瑞婷,等. 糖尿病足患者抑郁发生的影响因素[J]. 实用医学杂志, 2016, 32(5):83-86.
[7] Akila M, Ramesh RS, Kumari MJ.Assessment of diabetic foot risk among diabetic patients in a tertiary care hospital, South India[J]. J Educ Health Promot, 2021,10:14.
[8] Van Netten J, Bakker K, Apelqvist J, et al.The 2015 guidance of the International Working Group on the Diabetic Foot[J]. EWMA J, 2016, 16(1):11-14.
[9] Wagner FW.The dysvascular foot: a system for diagnosis and treatment[J]. Foot Ankle, 1981,2(2):64-122.
[10] 安静思, 赵锦, 王雪鹰. 重症糖尿病足及糖尿病足截肢影响因素分析[J]. 中国全科医学,2018, 21(26):48-54.
[11] Aziz Z, Lin WK, Nather A,et al.Predictive factors for lower extremity amputations in diabetic foot infections[J]. Diabet Foot Ankle, 2011, 2.
[12] Santos VPD, Silveira DRD, Caffaro RA.Risk factors for primary major amputation in diabetic patients[J]. Sao Paulo Med J, 2006,124(2):66-70.
[13] 张竞,罗蕴之,李素丽,等.新疆乌鲁木齐维吾尔族≥18岁居民糖尿病患病率及其影响因素调查[J].中国热带医学,2020,20(9):826-830+838.
[14] Shen J, Liu F, Zeng H, et al.Vibrating Perception Threshold and Body Mass Index Are Associated with Abnormal Foot Plantar Pressure in Type 2 Diabetes Outpatients[J]. Diabetes Technol Ther, 2012,14(11):1053-1059.
[15] Mukendi I, Mundawarara S, Luvhengo T.Factors leading to delayed presentation of patients with diabetic foot sepsis at regional hospitals in the Ekurhuleni Metropolitan Municipality of Gauteng province[J]. S Afr J Surg, 2017,55(2):68.
[16] Kow RY,Low CL,Ruben JK, et al.Predictive Factors of Major Lower Extremity Amputations in Diabetic Foot Infections: A Cross-sectional Study at District Hospital in Malaysia[J]. Malays Orthop J, 2019,13(3):45-52.
[17] Ang GY, Yap CW, Saxena N.Effectiveness of Diabetes Foot Screening in Primary Care in Preventing Lower Extremity Amputations[J]. Ann Acad Medicine Singap, 2017, 46(11):417-423.
[18] Jiang Y, Ran X, Jia L,et al.Epidemiology of type 2 diabetic foot problems and predictive factors for amputation in China[J]. Int J Low Extrem Wounds,2015, 14(1):19-27.
[19] Kaplan ST, Hemsinli D, Kaplan S,Arslan A.Amputation predictors in diabetic foot ulcers treated with hyperbaric oxygen[J]. J Wound Care, 2017,26(7):361-366.
[20] 刘薇,张如意,刘剑烽,等.糖尿病足溃疡面病原菌与影响因素分析[J].实用医学杂志,2019,35(15):2443-2446.
[21] Choi Ms, Jeon S, Lee J.Predictive factors for successful limb salvage surgery in diabetic foot patients[J]. BMC Surgery, 2014,14:113.
[22] Costa RHR, Cardoso NA, Procópio RJ.Diabetic foot ulcer carries high amputation and mortality rates, particularly in the presence of advanced age, peripheral artery disease and anemia[J]. Diabetes Metab Syndr, 2017,11(Suppl 2):S583-S587.
[23] 王宁, 鞠上, 杨博华, 等.糖尿病足患者大截肢危险因素的Meta分析[J].中华糖尿病杂志,2018,10(7):465-470.

mFOLFOX系统性化疗联合靶向免疫方案治疗不可切除肝细胞癌的真实世界数据初步分析

Real-world analysis of mFOLFOX systemic chemotherapy combined with immunotherapy and targeted therapy for unresectable hepatocellular carcinoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 1

编辑推荐

Metrics